ライフサイエンスコーパス: phase I clinical trial

1 ipheral blood mononuclear cells (PBMCs) in a phase I clinical trial.

2 ) targeting GD2-positive CNS/LM disease in a phase I clinical trial.

3 patients (6 cohorts of 4 patients each) in a phase I clinical trial.

4 AZD9496 is currently being evaluated in a phase I clinical trial.

5 ) is a candidate for possible advancement to phase I clinical trial.

6 approach that is currently the subject of a phase I clinical trial.

7 all-cell lung cancer (NSCLC), we conducted a phase I clinical trial.

8 (17-AGG) is an Hsp90 inhibitor currently in Phase I clinical trial.

9 u-expressing breast and ovarian cancers in a phase I clinical trial.

10 L, helper T lymphocytes, and antibodies in a phase I clinical trial.

11 o patients without complication as part of a phase I clinical trial.

12 the safety and activity of hOKT3gamma4 in a Phase I clinical trial.

13 15 was shown to have no adverse effects in a Phase I clinical trial.

14 rophic lateral sclerosis (ALS) patients in a Phase I clinical trial.

15 ased in patients treated with PBI-05204 in a phase I clinical trial.

16 no dose-limiting toxicity was observed in a Phase I clinical trial.

17 umor-bearing mice and cancer patients from a phase I clinical trial.

18 ic castration-resistant prostate cancer in a phase I clinical trial.

19 s (NYVAC-C) showed limited immunogenicity in phase I clinical trials.

20 NVP-AUY922 has entered phase I clinical trials.

21 for clinical evaluation and is currently in phase I clinical trials.

22 in intact cells and is currently undergoing phase I clinical trials.

23 is being evaluated as an anticancer drug in phase I clinical trials.

24 irst subunit tuberculosis vaccine to undergo phase I clinical trials.

25 rrolobenzodiazepine (PBD) dimer currently in phase I clinical trials.

26 murine orthopoxvirus models and has entered Phase I clinical trials.

27 p38 which was selected for advancement into Phase I clinical trials.

28 ry favorable risk-benefit profile, and is in phase I clinical trials.

29 onate salt of 32, designated DPC168, entered phase I clinical trials.

30 MLN944 has recently entered Phase I clinical trials.

31 s in animal models and was well tolerated in Phase I clinical trials.

32 n dosed at 160 mg/kg BID and is currently in Phase I clinical trials.

33 ylaminogeldanamycin (17-AAG) is currently in phase I clinical trials.

34 Compound 17 has been taken into phase I clinical trials.

35 odels but also provided promising results in phase I clinical trials.

36 preliminary data that have emerged from the phase I clinical trials.

37 A and other HDAC inhibitors are currently in Phase I clinical trials.

38 unine is a novel Vinca alkaloid presently in Phase I clinical trials.

39 eutic approach to cancer treatment and is in Phase I clinical trials.

40 8 activity in cancer patients are ongoing in Phase I clinical trials.

41 of a new class of anticancer drugs to enter phase I clinical trials.

42 SCH 66336 is presently being evaluated in Phase I clinical trials.

43 e CA IX inhibitor (SLC-0111) is presently in phase I clinical trials.

44 ignant melanoma, and is currently undergoing Phase I clinical trials.

45 elected for further development, and entered phase I clinical trials.

46 MKT-077 is now being investigated in Phase I clinical trials.

47 ehenate (TDB) is a new adjuvant currently in phase I clinical trials.

48 N-deficient cancers and has recently entered phase I clinical trials.

49 5838 (MI-77301), that has been advanced into phase I clinical trials.

50 modulator has successfully progressed beyond phase I clinical trials.

51 tor prodrug, SF1126, which has now completed Phase I clinical trials.

52 itor of the NEDD8-activating enzyme (NAE) in phase I clinical trials.

53 ne of our inhibitors is currently undergoing phase I clinical trials.

54 investigational small molecule currently in phase I clinical trials.

55 bromodomain inhibitor that recently entered phase I clinical trials.

56 > 50%), and is currently under evaluation in phase I clinical trials.

57 port the evaluation of this vaccine virus in phase I clinical trials.

58 -4-carboxamide, ABT-888), currently in human phase I clinical trials.

59 models and is currently under evaluation in phase I clinical trials.

60 ETi at effective doses have been reported in phase I clinical trials.

61 peptide receptor (GRP-R) and is currently in phase I clinical trials.

62 lay in a HT-29 model) and is now in multiple phase I clinical trials.

63 l safety profiles, 10 has been advanced into phase I clinical trials.

64 cleotide-based therapies have been tested in phase I clinical trials, a quarter of which have reached

65 Early preclinical studies and phase I clinical trials achieved promising results with

66 lso known as DENSPM) is currently undergoing Phase I clinical trials against solid tumors.

67 However, in phase I clinical trials, alpha-GalCer was shown to displ

68 ferent carcinomas and has recently completed phase I clinical trials and is being evaluated in phase

69 ridine], an antitumor agent, is currently in Phase I clinical trials and is believed to be a prodrug.

70 One Hsp90 inhibitor, 17-AAG, has completed Phase I clinical trial, and several Phase II trials are

71 orinated form, flavopiridol, is currently in phase I clinical trials as a drug against breast tumors.

72 -dioxoolean-1,9-dien-28-oate (CDDO-Me) is in phase I clinical trials as a novel cancer therapeutic ag

73 d for further evaluation and is currently in phase I clinical trials as a potential atypical antipsyc

74 one of them is currently being evaluated in Phase I clinical trials as a treatment for solid tumors.

75 numerous tumor models and was advanced into phase I clinical trials as the water-soluble N,N-dimethy

76 er agents currently under investigation in a Phase I clinical trial at the National Institutes of Hea

77 ions in vivo supported the initiation of two phase I clinical trials at the NCI to evaluate clofarabi

78 She declined participation in a phase I clinical trial because she was afraid of experie

79 verexpressing the protein was evaluated in a phase I clinical trial but failed to induce neutralizing

80 yme resulted in DMP323, which was studied in phase I clinical trials but found to suffer from variabl

81 dels as well as promising safety profiles in phase I clinical trials, but has failed to demonstrate s

82 Aza-epothilone B has been advanced to phase I clinical trials by the Bristol-Myers Squibb grou

83 Conclusion: This first-in-human, phase I clinical trial demonstrates the safe use and cli

84 This first-in-human, phase I clinical trial demonstrates the safe use and cli

85 born error of metabolism were eligible for a phase I clinical trial designed to estimate the risk of

86 The model is being used for phase I clinical trial designs for AZD6738, with the aim

87 In addition, a phase I clinical trial evaluating autologous T-Rapa cell

88 s Administration (TGA) prior to conducting a Phase I clinical trial evaluating the safety and tolerab

89 Several phase I clinical trials eventually yielded dramatic resu

90 As a first step into human gene therapy, a phase I clinical trial for assessing the feasibility and

91 lopment of HC-Ad-TK/TetOn-Flt3L for a future phase I clinical trial for GBM.

92 CX-5461 is now in advanced phase I clinical trial for patients with BRCA1/2 deficie

93 ist (related to SP-G), which has completed a phase I clinical trial for SCLC.

94 ovel polyamine analogue that has completed a phase I clinical trial for the treatment of cancer.

95 r further evaluation and has progressed into Phase I clinical trial for the treatment of cancer.

96 d IgG1 antihuman CD40 that is currently in a phase I clinical trial for the treatment of multiple mye

97 d I-BET762 is currently being evaluated in a phase I clinical trial for treatment of human cancer.

98 e Aurora A kinase inhibitor that has entered Phase I clinical trials for advanced solid tumors.

99 potent protein kinase inhibitor currently in phase I clinical trials for cancer treatment, abrogates

100 ubility, 1a is currently under evaluation in Phase I clinical trials for cancer.

101 as low as 1 mg/kg orally and is currently in phase I clinical trials for cancer.

102 nd, importantly, there are 2 newly initiated phase I clinical trials for HF gene therapy.

103 Preclinical and phase I clinical trials for low-risk prostate cancer hav

104 and supports the evaluation of this agent in Phase I clinical trials for patients with B-CLL.

105 Deltagamma(1)34.5 virus expressing IL-12 to phase I clinical trials for patients with recurrent mali

106 species that is currently being evaluated in phase I clinical trials for the treatment of advanced es

107 nhibitor of Rev function and is currently in phase I clinical trials for the treatment of AIDS patien

108 cted for further studies and is currently in phase I clinical trials for the treatment of cancer.

109 cted for further studies and is currently in phase I clinical trials for the treatment of cancer.

110 12b is currently in phase I clinical trials for the treatment of cancers.

111 (GDC-0623 and G-573, the former currently in phase I clinical trials) form a strong hydrogen-bond int

112 Patients with advanced sarcoma treated on phase I clinical trials had a clinical benefit rate of 3

113 UCN-01, an anticancer agent currently in Phase I clinical trials, has been found to potentiate th

114 Participants in phase I clinical trial have high expectations regarding

115 Phase I clinical trials have been performed with 1 of th

116 Phase I clinical trials have been successfully conducted

117 Phase I clinical trials have shown that ex vivo expanded

118 In the phase I clinical trial, headache was the dose-limiting t

119 ylhydrazone (A-007) has recently completed a phase I clinical trial in advanced cancer with minimal t

120 Compound 18 was recently evaluated in a phase I clinical trial in cancer patients.

121 In a phase I clinical trial in patients chronically infected

122 vivo in preclinical animal models, and in a phase I clinical trial in patients with advanced cancers

123 A phase I clinical trial in patients with advanced carcino

124 ination with gemcitabine in a first-in-human phase I clinical trial in patients with advanced solid t

125 the saponin immunologic adjuvant QS21, in a phase I clinical trial in patients with biochemically re

126 representative lead compound currently in a phase I clinical trial in patients with cancer.

127 In this phase I clinical trial in patients with first ST-elevati

128 conjugate targeting CD19, in a first-in-man phase I clinical trial in patients with relapsed lymphom

129 pound 30 (MK-0731) was recently studied in a phase I clinical trial in patients with taxane-refractor

130 al PCA model, which may form the basis for a Phase I clinical trial in PCA patients.

131 e similarly active in humans, we conducted a Phase I clinical trial in which high-risk acute myeloid

132 rt SF1126 as a viable pan PI3K inhibitor for phase I clinical trials in cancer and provide support fo

133 Orally administered CEP-7055 has entered Phase I clinical trials in cancer patients.

134 in preclinical models and is now undergoing phase I clinical trials in cancer patients.

135 Since the inception of phase I clinical trials in cancer, patients with symptom

136 than 5 years ago have already progressed to phase I clinical trials in healthy human adults.

137 rejection in animal models and currently in phase I clinical trials in human transplant recipients.

138 fashion and an initial lead compound entered phase I clinical trials in late 2007.

139 gression as shown in preclinical studies and phase I clinical trials in non-small cell lung cancer.

140 e provide a comprehensive review of adaptive phase I clinical trials in oncology that used a statisti

141 ments (eg, stem cells, gene transfer) before phase I clinical trials in patients; basic research on d

142 A4 phosphate prodrug is currently undergoing phase I clinical trials in the UK and USA.

143 valuations on this novel agent in support of phase I clinical trials in the United Kingdom and the Un

144 n (mTOR) inhibitor currently being tested in phase I clinical trials, in radiosensitization.

145 Phase I clinical trials indicated that 2, the first clin

146 ommunication and informed consent process in phase I clinical trial interviews to provide authentic,

147 We conducted a Phase I clinical trial investigating the biologic activi

148 are at present conducting the first in-human phase I clinical trial involving the systemic administra

149 nent of a novel anticancer agent (AFP464) in phase I clinical trials, is a ligand of the aryl hydroca

150 Mtb72F in AS02A formulation is currently in phase I clinical trial, making it the first recombinant

151 In proof-of-concept and phase I clinical trials, MSC therapy improved left ventr

152 , which is currently being investigated in a phase I clinical trial (NCT02237638), can potentially ou

153 tion of patient blood and bone marrow from a phase I clinical trial of a Pim kinase inhibitor, AZD120

154 We conducted a phase I clinical trial of a virosomal H5N1 vaccine adjuv

155 We conducted a phase I clinical trial of BR96-Doxorubicin (BR96-Dox), a

156 In a phase I clinical trial of CDDO (RTA-401) in leukemia, CD

157 evance to translation in the clinic, where a Phase I clinical trial of DARC in glaucoma patients is d

158 In a phase I clinical trial of ex vivo gene therapy of p47pho

159 We designed a phase I clinical trial of FU in combination with UCN-01.

160 As part of a Phase I Clinical Trial of human tolerance to LTB4, four

161 as rationale for our recent initiation of a phase I clinical trial of immunization with autologous t

162 he antitumor immune response, we conducted a phase I clinical trial of immunization with ESO(157-170)

163 We conducted a multicenter, dose-escalation, phase I clinical trial of NP2, a replication-defective H

164 Consequently, we undertook a phase I clinical trial of p53 gene therapy using an aden

165 A phase I clinical trial of PVSRIPO with intratumoral inoc

166 We therefore designed a phase I clinical trial of sequential paclitaxel and flav

167 s performed in seven healthy volunteers in a phase I clinical trial of the gadolinium chelate MS-325.

168 The results of a phase I clinical trial of the topoisomerase I (Topo I) p

169 A phase I clinical trial of this immunization strategy in

170 A phase I clinical trial of this vaccination strategy in p

171 In the first Phase I clinical trials of endostatin as an antiangiogen

172 Phase I clinical trials of new anticancer therapies dete

173 Four phase I clinical trials of the safety of gene transfer i

174 In 2006, a first-in-man phase-I clinical trial of an immunomodulatory mAb, TGN14

175 of the European guidelines for first-in-man phase-I clinical trials of biologics.

176 In a Phase I clinical trial open to patients with refractory

177 which first in class inhibitor that entered phase I clinical trials over the last five years and als

178 was a cancer patient who participated in the phase I clinical trial program at the University of Chic

179 protease inhibitor, BILN 2061, for which the Phase I clinical trial results were reported recently.

180 cific antisense oligonucleotide currently in phase I clinical trials robustly induces apoptosis, rega

181 though it would be enormously challenging, a phase I clinical trial seems feasible and needed to dete

182 as transitioning from preclinical studies to phase I clinical trial status.

183 These small Phase I clinical trials suggest that this approach is sa

184 l chemistry rationale, preclinical data, and phase I clinical trial summary for this new agent are re

185 Data from a phase I clinical trial testing MABT is consistent with t

186 We conducted a phase I clinical trial testing the biologic activity of

187 Here we report the results of a phase I clinical trial that tested the safety and effica

188 Thirty cancer patients enrolling in phase I clinical trials, their physicians, and their res

189 n these vaccine candidates were evaluated in phase I clinical trials, there were inconsistencies betw

190 A Phase I clinical trial to combine IFN-alpha-2a and/or RA

191 We conducted a single-institution phase I clinical trial to determine the maximum-tolerate

192 We conducted a phase I clinical trial to test the safety and biologic e

193 as a clinical candidate for advancement into phase I clinical trials to assess safety and tolerabilit

194 s sequentially, enabling the use of existing phase I clinical trial toxicity data.

195 A phase I clinical trial using a combination of trientine

196 In this study, we performed a phase I clinical trial using a mouse monoclonal antibody

197 unization in cancer patients, we performed a phase I clinical trial using dendritic cells pulsed with

198 d 102 advanced cancer patients enrolled onto phase I clinical trials using a standardized survey that

199 A phase I clinical trial was conducted to evaluate the saf

200 A standard 2-dose-escalation phase I clinical trial was conducted with 12 patients.

201 ministering 1 to healthy human volunteers, a phase I clinical trial was conducted.

202 This phase I clinical trial was designed to determine the max

203 The aim of this first-in-human, phase I clinical trial was to investigate the safety and

204 he subsequent results of small nonrandomized phase-I clinical trials, was then tempered by the subseq

205 atients treated with intravenous JX-594 in a phase I clinical trial, we showed dose-dependent endothe

206 In vitro studies and a phase I clinical trial were performed.

207 eported, to 1998 when results from the first phase I clinical trials were described.

208 Here, we report the results from the initial phase I clinical trial where 24 patients with different

209 umber of preclinical models before moving to phase I clinical trials, where it showed excellent human

210 Data from refractory cancer patients in a Phase I clinical trial with CM101 indicated a similar me

211 A phase I clinical trial with granulocyte-macrophage colon

212 n of apoC-III in preclinical models and in a phase I clinical trial with healthy subjects produced po

213 Therefore, we have begun a Phase I clinical trial with IL-4(38-37)-PE38KDEL for tre

214 Phase I clinical trials with fostriecin, which were the

215 Phase I clinical trials with this agent have shown a fav

216 Chk1/2-targeted agent, AZD7762, currently in phase I clinical trials, with gemcitabine and ionizing r

217 s Perspective includes an essay on modifying phase I clinical trials, written by George Zimmer, who w